NEW YORK (GenomeWeb) – CombiMatrix today reported that its second quarter revenues rose 29 percent year over year, driven by 60 percent growth in prenatal microarray testing volumes.

For the three months ended June 30, the Irvine, Calif.-based molecular diagnostics company saw revenues climb to $1.9 million from $1.5 million in the second quarter of 2013. Its revenues were in line with the consensus Wall Street estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.